Autolus Therapeutics (AUTL) Accumulated Depreciation (2018 - 2019)
Autolus Therapeutics posted quarterly Accumulated Depreciation of -$4.8 million for Q1 2019, down 230.02% on a QoQ basis from $3.7 million in Q4 2018.
Autolus Therapeutics (AUTL) has 2 years of Accumulated Depreciation data on file, last reported at -$4.8 million in Q1 2019.
- For the quarter ending Q1 2019, Accumulated Depreciation changed N/A year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2019 stood at -$4.8 million (changed N/A YoY), and the FY2018 full-year result was $3.7 million, changed N/A from the prior year.
- Accumulated Depreciation for Q1 2019 stood at -$4.8 million, down from $3.7 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $3.7 million in Q4 2018 and bottomed at -$4.8 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | -4.82 Mn |
| Dec 31, 2018 | 3.71 Mn |